eCite Digital Repository

Gene therapy with endogenous inhibitors of angiogenesis for neovascular age-related macular degeneration: Beyond anti-VEGF therapy

Citation

Prea, SM and Chan, EC and Dusting, GJ and Vingrys, AJ and Bui, BV and Liu, GS, Gene therapy with endogenous inhibitors of angiogenesis for neovascular age-related macular degeneration: Beyond anti-VEGF therapy, Journal of Ophthalmology, 2015 Article 201726. ISSN 2090-004X (2015) [Refereed Article]


Preview
PDF
231Kb
  

Copyright Statement

Copyright 2015 Selwyn M. Prea et al. Licensed under Creative Commons Attribution 3.0 Unported (CC BY 3.0) https://creativecommons.org/licenses/by/3.0/

DOI: doi:10.1155/2015/201726

Abstract

Age-related macular degeneration (AMD) is the leading cause of substantial and irreversible vision loss amongst elderly populations in industrialized countries. The advanced neovascular (or "wet") form of the disease is responsible for severe and aggressive loss of central vision. Current treatments aim to seal off leaky blood vessels via laser therapy or to suppress vessel leakage and neovascular growth through intraocular injections of antibodies that target vascular endothelial growth factor (VEGF). However, the long-term success of anti-VEGF therapy can be hampered by limitations such as low or variable efficacy, high frequency of administration (usually monthly), potentially serious side effects, and, most importantly, loss of efficacy with prolonged treatment. Gene transfer of endogenous antiangiogenic proteins is an alternative approach that has the potential to provide long-term suppression of neovascularization and/or excessive vascular leakage in the eye. Preclinical studies of gene transfer in a large animal model have provided impressive preliminary results with a number of transgenes. In addition, a clinical trial in patients suffering from advanced neovascular AMD has provided proof-of-concept for successful gene transfer. In this mini review, we summarize current theories pertaining to the application of gene therapy for neovascular AMD and the potential benefits when used in conjunction with endogenous antiangiogenic proteins.

Item Details

Item Type:Refereed Article
Research Division:Technology
Research Group:Medical Biotechnology
Research Field:Gene and Molecular Therapy
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Inherited Diseases (incl. Gene Therapy)
Author:Liu, GS (Dr Guei-Sheung Liu)
ID Code:120856
Year Published:2015
Web of Science® Times Cited:1
Deposited By:Menzies Institute for Medical Research
Deposited On:2017-08-31
Last Modified:2017-11-06
Downloads:21 View Download Statistics

Repository Staff Only: item control page